David Ensz, MD
Family Medicine · South Sioux City, NENPI 1124245899
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,462 of the $3,851 with a category attached, or 89.9%. It is spread thinly across 32 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,141 and has fallen 95.4% since, to $52 in 2025.
Across 241 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$598
- AbbVie$544
- AstraZeneca$461
- Amgen$377
- Sanofi$260
- Sanofi-aventis U.S. LLC$174
- plus $1K from 26 others
Across 5,394 payments — averaging $6165.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$20M
- Pfizer$7.3M
- Seqirus USA Inc$2.4M
- Valneva Austria GmbH$623K
- Novavax Inc$477K
- Johnson & Johnson$440K
- plus $2M from 18 others
What the payments were for
- Speaking & faculty fees$2456%
- Food & beverage$3,46290%
- Education$1233%
- Gifts$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $598 |
| AbbVie(2 entities) | 46 | $544 |
| AstraZeneca | 15 | $461 |
| Amgen | 26 | $377 |
| Sanofi | 3 | $260 |
| Sanofi-aventis U.S. LLC | 12 | $174 |
| Amarin Pharma, Inc. | 10 | $156 |
| Astellas Pharma US Inc | 4 | $147 |
| Pfizer | 13 | $133 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $132 |
| Bayer | 7 | $112 |
| Xeris Pharmaceuticals, Inc. | 5 | $103 |
| Kowa Pharmaceuticals America, Inc. | 7 | $103 |
| Boehringer Ingelheim | 6 | $87 |
| Merck | 4 | $66 |
| Sunovion Pharmaceuticals Inc. | 6 | $51 |
| Lilly USA, LLC | 4 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $37 |
| Genentech USA, Inc. | 2 | $31 |
| GSK | 2 | $28 |
| Abbott | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 3 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,851 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 249 | $168,886 |
| OzempicSemaglutide | 103 | $119,752 |
| FarxigaDapagliflozin Propanediol | 95 | $87,543 |
| TrulicityDulaglutide | 45 | $74,817 |
| MounjaroTirzepatide | 54 | $72,199 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $46,956 |
| RybelsusSemaglutide | 33 | $43,768 |
| LinzessLinaclotide | 31 | $30,309 |
| EntrestoSacubitril/Valsartan | 70 | $30,176 |
| MyrbetriqMirabegron | 64 | $29,870 |
| JanuviaSitagliptin Phosphate | 25 | $29,281 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $28,961 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $28,635 |
| Repatha SureclickEvolocumab | 45 | $28,456 |
| JardianceEmpagliflozin | 28 | $28,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $133 | $168,886249 claims |
| Novo NordiskOzempic, Rybelsus | $598 | $163,520136 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $47 | $147,01699 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $461 | $115,816162 claims |
| AbbVieLinzess, Qulipta, Vraylar | $544 | $54,94057 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $28 | $53,93187 claims |
| MerckJanuvia, Belsomra | $66 | $34,83937 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $87 | $34,44341 claims |
| NovartisEntresto | $13 | $30,17670 claims |
| Astellas Pharma US IncMyrbetriq | $147 | $29,87064 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.
Other family medicine in South Sioux City
- Michael BrennerSouth Sioux City$17K
- Thomas WenteSouth Sioux City$9K
- Michael HattanSouth Sioux City$9K
- Melissa Austreim-KrellSouth Sioux City$7K
- Michael IsraelLincoln$375K
- Francisco DozonNorfolk$238K
- Randy KohlLincoln$67K
- James OmelGrand Island$67K
- Gerard StanleyOmaha$50K
- Jared KramerSt Paul$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.